Auswahl der wissenschaftlichen Literatur zum Thema „Moths – ireland – identification“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Moths – ireland – identification" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Moths – ireland – identification"
1
Frankis, Jamie, Paul Flowers, Lisa McDaid und Adam Bourne. „Low levels of chemsex among men who have sex with men, but high levels of risk among men who engage in chemsex: analysis of a cross-sectional online survey across four countries“. Sexual Health 15, Nr. 2 (2018): 144. http://dx.doi.org/10.1071/sh17159.
Der volle Inhalt der QuelleAnnotation:
Background This paper establishes the prevalence of chemsex drug use among men who have sex with men (MSM), the extent to which these drugs are used in a sexual context, as well as their associated behaviours and circumstances of use. Methods: Data from a cross-sectional, online survey of 2328 MSM recruited via gay sociosexual media in Scotland, Wales, Northern Ireland and the Republic of Ireland were analysed. Results: While almost half (48.8%) of participants had ever taken illicit drugs, lifetime chemsex drug use was less common (18.0%) and far fewer reported chemsex drug use in the last year (8.2%) or last 4 weeks (3.0%). Just over one-quarter (27.1%) of men who used chemsex drugs in the last year reported no sexualised drug use, but almost three-quarters (72.9%) did. Only 6.1% of the whole sample reported sexualised chemsex drug use in the last year. The odds of reporting chemsex in the last year were significantly higher for men aged 36–45 years (AOR = 1.96), single men (AOR = 1.83), men who were HIV positive (AOR = 4.01), men who report high-risk sex (AOR = 4.46), being fisted (AOR = 7.77) or had sex in exchange for goods other than money (AOR = 4.7) in the last year and men who reported an HIV test in the last 3 months (AOR = 1.53). Discussion: Only a small proportion of MSM in Scotland, Wales, Northern Ireland and the Republic of Ireland reported chemsex, and, for the first time, it is demonstrated that not all chemsex drug use was sexualised. Nevertheless, MSM who engage in chemsex (MWEC) reported substantial sexual risk inequalities. These novel findings highlight several opportunities for intervention, particularly around the multiple vulnerabilities of MWEC, opportunities for early identification of those most vulnerable to chemsex-related harm and the potential to develop a specialised responsive patient pathway.
2
Beresford, Robert M., und Kwang Soo Kim. „Identification of Regional Climatic Conditions Favorable for Development of European Canker of Apple“. Phytopathology® 101, Nr. 1 (Januar 2011): 135–46. http://dx.doi.org/10.1094/phyto-05-10-0137.
Der volle Inhalt der QuelleAnnotation:
Months of the year with high risk of European canker (Neonectria galligena) development in areas of the United States, Chile, England, and Northern Ireland were determined from published data. Moving-window analysis of long-term climatic data was used to classify disease risk in these areas in relation to rainfall and temperature conditions using the degree of agreement statistic. Greatest agreement occurred when it both rained on >30% of days/month and there was an average of >8 h/day with temperature of 11 to 16°C. When these thresholds were applied in eight validation areas in New Zealand, Australia, the United States, The Netherlands, and Denmark, areas with reported higher risk of disease tended to be areas where the thresholds were exceeded more often and by greater amounts. Areas at higher latitudes (>52°) with frequent summer rainfall appeared to be most prone to European canker, including the fruit rot phase of the disease, probably because summer temperatures were more favorable than at lower latitudes. The climatic thresholds derived for European canker could be useful for studies of disease establishment risk, surveillance, eradication, climate change impact assessment, and, possibly, for disease risk forecasting. The methods used in this study allowed conditions favorable for disease development to be identified even though quantitative regional disease data were lacking, and they could be useful for similar geoclimatic studies of other diseases.
3
Garry, P., P. Collins und JG Devlin. „An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency“. European Journal of Endocrinology 134, Nr. 1 (Januar 1996): 61–66. http://dx.doi.org/10.1530/eje.0.1340061.
Der volle Inhalt der QuelleAnnotation:
Garry P. Collins P. Devlin JG. An open 36 month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996:134:61–6. ISSN 0804–4643 Interest in adult growth hormone replacement has increased since identification of the associated vascular morbidity and mortality. Although total cholesterol and low density lipoprotein reduction and high density lipoprotein increases are anticipated, reports are conflicting and there is no uniformity in lipoprotein(a) changes. In 1990 we commenced an open trial of therapy with human recombinant GH and now have results to 36 months for 21 patients. Deficiency status was confirmed by insulin stress test with flat GH response <2.0 ng/ml, mean insulin-like growth factor-I value 122 ng/ml (±69 SD). Lipoprotein(a) was measured by monoclonal assay. Lipid analysis yields two subgroups: baseline cholesterol levels of greater or less than 6.22 mmol/l, with hypercholesterolaemic patients showing an enhanced hypolipaemic response. ANOVA was utilized, with 95% confidence limits. The most significant changes are of reductions in cholesterol and low density lipoprotein: the rate of change is greatest at 6 and 12 months but not sustained to 36 months. High density lipoprotein rises as expected, not to full significance. Lipoprotein(a) levels rose significantly in six patients of the cohort, and the increase was sustained over 36 months. JG Devlin, Department of Endocrinology, Beaumont Hospital. Dublin 9. Ireland
4
Flynn, Maureen A., Thora Burgess und Philip Crowley. „Supporting and activating clinical governance development in Ireland: sharing our learning“. Journal of Health Organization and Management 29, Nr. 4 (15.06.2015): 455–81. http://dx.doi.org/10.1108/jhom-03-2014-0046.
Der volle Inhalt der QuelleAnnotation:
Purpose – The purpose of this paper is to present a description of the Irish national clinical governance development initiative and an evaluation of the initiative with the purpose of sharing the learning and proposing actions to activate structures and processes for quality and safety. The Quality and Patient Safety Division of the Health Service Executive established the initiative to counterbalance a possible focus on finances during the economic crisis in Ireland and bring attention to the quality of clinical care. Design/methodology/approach – A clinical governance framework for quality in healthcare in Ireland was developed to clearly articulate the fundamentals of clinical governance. The project plan involved three overlapping phases. The first was designing resources for practice; the second testing the implementation of the national resources in practice; and the third phase focused on gathering feedback and learning. Findings – Staff responded positively to the clinical governance framework. At a time when there are a lot of demands (measurement and scrutiny) the health services leads and responds well to focused support as they improve the quality and safety of services. Promoting the use of the term “governance for quality and safety” assisted in gaining an understanding of the more traditional term “clinical governance”. The experience and outcome of the initiative informed the identification of 12 key learning points and a series of recommendations Research limitations/implications – The initial evaluation was conducted at 24 months so at this stage it is not possible to assess the broader impact of the clinical governance framework beyond the action project hospitals. Practical implications – The single most important obligation for any health system is patient safety and improving the quality of care. The easily accessible, practical resources assisted project teams to lead changes in structures and processes within their services. This paper describes the fundamentals of the clinical governance framework which might serve as a guide for more integrative research endeavours on governance for quality and safety. Originality/value – Experience was gained in both the development of national guidance and their practical use in targeted action projects activating structures and processes that are a prerequisite to delivering safe quality services.
5
Williams, Scott, Ian D. Davis, Christopher Sweeney, Martin R. Stockler, Andrew James Martin, Wendy Hague, Xanthi Coskinas et al. „Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303).“ Journal of Clinical Oncology 36, Nr. 6_suppl (20.02.2018): TPS156. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.tps156.
Der volle Inhalt der QuelleAnnotation:
TPS156 Background: Adjuvant ADT with an LHRH analog (LHRHA) given before, during and after radiotherapy (RT) is standard of care for high risk localised prostate cancer (PC). Enzalutamide improves overall survival (OS) in castration-resistant, metastatic prostate cancer. We hypothesized that the addition of enzalutamide to adjuvant ADT and RT will improve outcomes. The aim is to determine the effects of enzalutamide versus a conventional non-steroidal anti-androgen (NSAA) as part of neoadjuvant and adjuvant ADT in men undergoing RT for high risk, localized PC. Methods: DESIGN: Open label, randomised, phase 3 trial including ANZ, USA, UK, Ireland and Europe. ENDPOINTS: OS (primary), cause-specific survival, PSA progression free survival (PFS), clinical PFS, time to subsequent hormonal therapy, time to castration-resistant disease (PCWG2 criteria), metastasis free survival (MFS), adverse events and health-related quality of life (HRQOL). CORRELATIVE OBJECTIVES: identification of prognostic/predictive biomarkers from archival tumour tissue and serial blood samples. SAMPLE SIZE: 800 participants with a minimum follow-up of 5.5 yrs is designed to give 80% power to detect 33% reduction in the hazard of death assuming 5-year survival rate of 76% amongst controls. TREATMENT: Enzalutamide 160mg daily for 24 months versus conventional NSAA for 6 months. All participants receive LHRHA for 24 months, and RT starting about week 16 delivered as 78Gy in 39#, or 46Gy in 23# plus brachytherapy (nodal RT optional for N0, mandatory for N1). ASSESSMENTS: Baseline, then every 8 weeks until year 2, then 3-4 monthly until year 5, 6-monthly until year 7, then annually. Imaging with CT/MRI and bone scan at baseline, PSA progression, then 6 monthly until re-initiation of ADT, when PCWG2 criteria for CRPC are met and then 3 monthly until evidence of metastases. 623 participants recruited from 61 sites as of 16 October 2017. ENZARAD is an investigator-initiated cooperative group trial led by ANZUP Cancer Trials Group with funds and product from Astellas. Clinical trial information: NCT02446444.
6
Williams, Scott, Ian D. Davis, Christopher Sweeney, Martin R. Stockler, Andrew James Martin, Wendy Hague, Xanthi Coskinas et al. „Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).“ Journal of Clinical Oncology 35, Nr. 15_suppl (20.05.2017): TPS5096. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps5096.
Der volle Inhalt der QuelleAnnotation:
TPS5096 Background: Adjuvant ADT with an LHRH analog (LHRHA) given before, during and after radiotherapy (RT) is standard of care for high risk localised prostate cancer (PC). Enzalutamide is more effective in metastatic disease than conventional non-steroidal anti-androgens (NSAA). We hypothesize that addition of enzalutamide to adjuvant ADT and RT will improve outcomes. The aim is to determine the efficacy of enzalutamide compared with NSAA as part of adjuvant ADT with LHRHA in men planned for RT for localized high risk or node-positive PC. Methods: DESIGN: Open label, randomised, phase 3 trial including ANZ, USA, UK, Ireland and Europe. ENDPOINTS: OS (primary), cause-specific survival, PSA PFS, clinical PFS, time to subsequent hormonal therapy, time to castration-resistant disease (PCWG2 criteria), metastasis free survival, adverse events and HRQOL. Tertiary objectives: identification of prognostic/predictive biomarkers from archival tumour tissue and 4 serial fasting bloods. 800 target participants with 5.5 yrs minimum follow-up. 80% power to detect 33% reduction in the hazard of death assuming 5-year survival rate of 76% amongst controls. TREATMENT: Participants are randomised 1:1 to enzalutamide 160mg daily for 24 months versus conventional NSAA for 6 months. All participants receive LHRHA for 24 months and RT starting after week 16. RT delivered as 78Gy in 39 Fx or 46Gy in 23 Fx plus brachytherapy (nodal RT optional for N0, mandatory for N1). ASSESSMENTS: Baseline, then every 8 weeks until year 2, then 3-4 monthly until year 5, 6-monthly until year 7, then annually. CT/MRI and bone scan at baseline, PSA progression, 6 monthly until re-initiation of ADT, when PCWG2 criteria for CRPC are met and then 3 monthly until evidence of metastases. As of 1st February 2017, 55 of 67 sites open with 398 patients recruited. EORTC sites expected to open from Quarter 1 2017. ENZARAD is an investigator-initiated cooperative group trial led by ANZUP Cancer Trials Group with funds and product from Astellas. ANZUP is supported by Cancer Australia and previously CI NSW. ClinicalTrials.gov: NCT02446444, ANZCTR: ACTRN12614000126617 Clinical trial information: NCT02446444.
7
Codd, Y., R. Mullan, D. Kane, A. Coe und T. Stapleton. „POS0156-HPR ‘THE RIGHT ADVICE, IN THE RIGHT WAY AND AT THE RIGHT TIME’: AN INNOVATIVE MULTIDISCIPLINARY APPROACH TO ADDRESS CLIENT-IDENTIFIED PARTICIPATION NEEDS IN EARLY INFLAMMATORY ARTHRITIS“. Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 291.3–291. http://dx.doi.org/10.1136/annrheumdis-2021-eular.583.
Der volle Inhalt der QuelleAnnotation:
Background:Inflammatory arthritis (IA) is a complex life-long disease with negative consequences on occupational performance and significant impact on meaningful life roles. International guidelines for the clinical management of IA consistently recommend early intervention and a multidisciplinary (MDT) approach as the optimum method to address the medical, symptom and broader life impacts, however, barriers to timely access to the MDT is a common issue in clinical practice. Limited research has explored how clinical services support broader life impacts and participation restrictions associated with early disease as part of routine healthcare. Four rheumatology services in Ireland have recently reconfigured to provide an MDT-led early arthritis service which operates in parallel to traditional medical clinics. Staffed by nurses, occupational therapists, and physiotherapists this service provides assessment and management to clients with a new diagnosis of IA along a model of care within four to six weeks of diagnosis with mechanisms to follow the client over their first year of diagnosis.Objectives:To explore how a novel MDT-led early arthritis service addresses client-identified participation restrictions associated with early IA.Methods:A qualitative description (QD) study was used to explore the perspectives of service providers and service users of this MDT-led early arthritis service. Data were gathered using one-off focus groups with service providers, and individual interviews with service users.Results:All staff (n=15) currently working in these services participated in the focus groups. Forty-three service users with IA participated in individual interviews (males n=12: females n=31); diagnosis duration ranged from 5 to 24 months. QD principles and thematic analysis were used in data analysis.Extensive limitations in everyday activity and restriction in participation in meaningful, age-appropriate life roles in early IA were outlined by service users and service providers. Participants described how the MDT-led model provided automatic and immediate access to services focussed on identification and management of occupation-based participation restrictions early in the disease. Participants described how the model used a flexible approach that ensured; ease of early access to a full MDT, prolonged support from the MDT, and a person-centred approach incorporating social prescribing and self-management principles. Service users emphasised the strength of the MDT approach of providing ‘the right advice, in the right way and at the right time’ as the most influential feature that assisted them to address participation restrictions and support positive health outcomes. This was accomplished by the service providers acting in a coordinated and interdisciplinary manner with a clear remit to address participation restrictions alongside the traditional symptom management approach. Findings highlight the feasibility of the MDT-led early arthritis model as an approach to address participation-based restrictions as part of routine healthcare that delivers on the rheumatology guidelines and was positively regarded by both service users and service providers.Conclusion:Findings provide important insights into the role of an innovative early MDT intervention approach in addressing client-identified participation needs in early IA. This model maps onto the Irish rheumatology model of care (HSE, 2018), ‘right place, right time’ approach but importantly includes a ‘right way’ approach which is identified as influential in the effective delivery of client-focussed and client-centred care.References:[1]HSE. (2018). Model of care for rheumatology in Ireland. Retrieved 15/09/2019, https://www.hse.ie/eng/about/who/cspd/ncps/rheumatology/achievements/model-of-care-for-rheumatology-in-ireland.pdfAcknowledgements:The authors, thank you to the research sites who facilitated this study & the service providers and service users who partook in the research. Thank you to Kildare Branch of Arthritis Ireland who provided funding support for the researchDisclosure of Interests:None declared
8
Andrieu, Charlotte, Dalal Al-Sultan, Laura Ivers, Jose Javier Berenguer Pina, Darko Skrobo, Josephine Ballot, Alex J. Eustace et al. „The association of centromere amplification and response to trastuzumab in HER2+ metastatic breast cancer.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): 1016. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1016.
Der volle Inhalt der QuelleAnnotation:
1016 Background: Chromosomal instability and copy number aberration (CNA) burden can be associated with patients' survival in some cancers. Centromeres, chromosomal regions crucial for genomic stability, can be found altered by CNA in tumours but remain largely unexplored due to sequencing technologies. Using whole-genome sequencing (WGS) data from cases of long term, never relapsed HER2+ metastatic breast cancer (MBC) patients, also referred as exceptional responders (ExRs), we aim to better characterise the CNA profiles and underlying long-term survival of this “exceptional” cohort and investigate the centromeric and pericentromeric association with prognosis and treatment response. Methods: Two hundred and forty-three HER2+ MBC patients were enrolled in the HER2 Patients Project Database from St Vincent University Hospital, Dublin, Ireland. Eighty-five HER2+ MBC patients were identified as exceptional survivors (ExS) with an OS > 60 months (range 60-248 months), of which 28 never-relapsed and responded exceptionally (ExR) to trastuzumab. Patients with an OS < 60 months (N=158, range 0.2-59 months) were identified as non responders (NR). WGS was performed on 13 ExR tumours (primary or metastases) and matching control at a mean depth of 60X and 30X, respectively. Control-FREEC and CNVkit were used to characterise the CNA profiles and estimate the CNA burden. Samples from 10 NR patients were used for comparison with the ExR. Results: WGS analysis revealed that ExR samples are more impacted by gain rather than loss of copy overall, with a median fraction altered by gain of 0.24. No significant difference was observed between the ExR and NR in terms of CNA burden. However, a large fragment on chromosome 9 was amplified in 92% of ExR (12/13) which corresponded to the centromere (chr9q11) and a large heterochromatic block (chr9q12). A higher copy number status of this centromeric region was detected in the ExR, with a gain of at least 1 additional copy compared to the NR tumoral samples (P<0.001). The dichotomisation into high versus low copy number of the centromeric region of chromosome 9 was also observed in centromeres of chromosome 17 (P=0.009) and chromosome 19 (P<0.001). No case of polysomy was detected in our cohort and genes located near the centromeres, such as ERBB2 (amplified in both ExR and NR), were independent of the centromeres copy-number status. Conclusions: The identification of the genomic aberrations of these metastatic patients, treated with trastuzumab who never relapsed, increases our understanding of the mechanisms involved in MBC progression. Our results suggest that the centromere co-amplification of chr9q11-q12, chr17p11.1-q11.1 and chr19p11-q11 stratifies patients according to their OS. CNA status of the centromeric regions of chromosomes 9, 17 and 19 may therefore represent a novel prognostic predictor to trastuzumab response and new outcomes for patients.
9
Imtiaz, Nafiz, und John McLaughlin. „Reducing the Pressure on Mental Health Team by Improving Post-Discharge Follow-Up of Self-Harm or Suicidal Patients in Primary Care“. BJPsych Open 8, S1 (Juni 2022): S99. http://dx.doi.org/10.1192/bjo.2022.307.
Der volle Inhalt der QuelleAnnotation:
AimsNorthern Ireland has had the highest suicide and self-harm rate in the UK since 2012 according to National Statistics Office with 12.5 deaths per 100,000 population compared to 10.5 in the rest of the country. Evidence shows that the risk of suicide hugely increases following self-harm, and the greatest risk is immediately after the self-harm episode. Better access to health care, especially to primary care, in this period, can actively reduce the risk to this vulnerable patient group. Patients assessed for self-harm in the emergency department are often followed up by the mental health/crisis team. Due to lack of resources and staff shortages this is often not possible in a timely fashion. NICE suggests that patients should be offered a follow-up appointment in primary care within 48 hours of discharge. We aimed to ensure 70% of patients discharged from secondary care following an episode of suicidal ideation or self-harm are contacted proactively by mental health practitioner (MHP) or GP within 48 hours of communication from secondary care.MethodsThe project underwent two PDSA cycles. An electronic workflow was created to provide easy patient identification, assessment and follow-up. A process mapping was done after discussion with the GPs, administrative team, practice nurses and MHP. Outcome was measured by finding out percentage of patients: 1) Contacted within 48 hours of communication following an episode of self-harm 2) Appropriately coded 3) Comprehensively assessed 4) Risk stratified and minimized following each cycle.ResultsOver a period of three months, following two PDSA cycles, the frequency of these contacts increased from 0 to 80% (median) with an average 3.8 (83%) patients reviewed per week. The patient experience and satisfaction also improved significantly.ConclusionGeneral practice (GP) has long been known as the next of kin for patients in the health care system. As GP is mostly the first point of contact for the patients, it can contribute significantly to ease the rising pressure on the mental health team. Also, a small number of weekly contacts from each GP can make a huge difference in nationwide patient safety and experience. We hope this intervention will significantly improve patient safety and reduce further self-harm presentation to ED in the long run.
10
McKenna, Julie. „Evidence based research activities, interests and opportunities exist for practitioners in all library sectors in the British Isles“. Evidence Based Library and Information Practice 1, Nr. 1 (15.03.2006): 107. http://dx.doi.org/10.18438/b8kw2r.
Der volle Inhalt der QuelleAnnotation:
A review of:
McNicol, Sarah. “Is Research an Untapped Resource in the Library and Information Profession?” Journal of Librarianship and Information Science 36.3 (September 2004):119-26.
Objective – To scope the range, nature and challenges of present, planned and future research by practitioners within libraries in the British Isles.
Design – A series of survey questionnaires sent by mail.
Setting – Public, academic, health, special and school libraries of the British Isles.
Subjects – A total of 2384 questionnaires were sent out and 334 responses were received. 62 academic libraries, 83 health libraries, 78 public libraries, 63 school libraries and 48 special libraries participated in the study.
Methods – This study was undertaken in 2003 by a research team at the University of Central England. Survey questionnaires were sent by mail to library directors in all public library authorities, academic libraries, health libraries and special libraries in England, Wales, Scotland, Northern Ireland and the Republic of Ireland. In addition, questionnaires were sent to the librarians in all state and independent schools within a sample of nine local education authorities.
Each participant was asked to identify past and future research issues of interest and the barriers to research practice within their library. Research was defined to include work on both externally funded and in-house projects and examples of the types of activities that this might include were provided.
Main results – Half the respondents reported that they had been involved in some form of research in the past two years, with the lowest level of involvement from school libraries and the highest in public libraries. Generally, only the library directly involved in conducting the research made use of the findings and a gap in the dissemination of results was identified across sectors. User surveys were the most common form of research undertaken across libraries and slightly fewer respondents intended to carry out research in the coming twelve months than had in the past (the area most commonly mentioned was user surveys). Information and communications technology (ICT) was an area of planned future research in all libraries, as were user needs and user behaviour. The most frequently cited barriers to research activity across all sectors were lack of time and financial resources. Staff skills and the lack of focus on practical problems to solve were indicated as a barrier in health, public and academic libraries.
Libraries reported a range of common uses for the research findings including: informing strategic and service planning; providing benchmarking data and measuring the effectiveness of services; identification of marketing and public relations opportunities; discovery of staff training needs; and use of the results to demonstrate the value of libraries to funding bodies.
Conclusion – This study provides insight into practitioner-focused areas of research interest and possible areas for future investigation. As the author reports in her conclusion, the survey results cannot be considered representative of the wider population.
Since research interests often overlap, a sector wide or cross-sectoral research approach should be considered to allow library staff to identify and resolve common problems. Wide dissemination of research results within the practitioner community would be of benefit to all. Greater communication between practitioner and information science communities is also encouraged, as these communities’ work is mutually beneficial.
Bücher zum Thema "Moths – ireland – identification"
1
Riley, Adrian M. British and Irish pug moths (Lepidoptera: Geometridae, Larentiinae, Eupitheciini): A guide to their identification and biology. Colchester, Essex, England: Harley, 2003.
Den vollen Inhalt der Quelle finden
2
Parsons, Mark, Andy Swash, David Newland und Robert Still. Britain's Day-Flying Moths: A Field Guide to the Day-Flying Moths of Britain and Ireland. Princeton University Press, 2013.
Den vollen Inhalt der Quelle finden
3
Swash, Andy, David Newland und Robert Still. Britain's Day-Flying Moths: A Field Guide to the Day-Flying Moths of Great Britain and Ireland, Fully Revised and Updated Second Edition. Princeton University Press, 2019.
Den vollen Inhalt der Quelle finden
4
Swash, Andy, David Newland und Robert Still. Britain's Day-Flying Moths: A Field Guide to the Day-Flying Moths of Great Britain and Ireland, Fully Revised and Updated Second Edition. Princeton University Press, 2019.
Den vollen Inhalt der Quelle finden
5
Swash, Andy, David Newland und Robert Still. Britain's Day-flying Moths: A Field Guide to the Day-flying Moths of Britain and Ireland. Princeton University Press, 2013.
Den vollen Inhalt der Quelle finden
6
Swash, Andy, David Newland und Robert Still. Britain's Day-Flying Moths: A Field Guide to the Day-Flying Moths of Britain and Ireland. Princeton University Press, 2013.
Den vollen Inhalt der Quelle finden
7
Field Guide to the Micro-Moths of Great Britain and Ireland: 2nd Edition. Bloomsbury Publishing Plc, 2023.
Den vollen Inhalt der Quelle finden
8
Waring, Paul. Field Guide to the Moths of Great Britain and Ireland. British Wildlife Publishing, 2003.
Den vollen Inhalt der Quelle finden
9
Waring, Paul. Field guide to the moths of Great Britain and Ireland. British Wildlife Publishing, 2003.
Den vollen Inhalt der Quelle finden
10
Waring, Paul, und Martin Townsend. Field Guide to the Moths of Great Britain and Ireland: Third Edition. Bloomsbury Wildlife, 2018.
Den vollen Inhalt der Quelle finden